Effect of CS-514 (pravastatin) on VLDL-triglyceride kinetics in rats

This publication has 26 references indexed in Scilit:

• Effects of CS-514 on plasma lipids and lipoprotein composition in hypercholesterolemic subjects
  Atherosclerosis, 1988
• CS-514 Suppresses Plasma Triglyceride in Hypertriglyceridemic Subjects Without Modifying a Lipoprotein Structural Model
  Hormone and Metabolic Research, 1987
• The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects
  Published by American Medical Association (AMA) ,1987
• PROBUCOL VERSUS EPTASTATIN IN HYPERCHOLESTEROLAEMIC DIABETICS
  The Lancet, 1986
• Effects of CS-514, a New Inhibitor of HMG CoA Reductase, on Plasma Lipids, Lipoproteins and Apoproteins in Patients with Primary Hypercholesterolemia
  Hormone and Metabolic Research, 1986
• The Effect of CS-514, an Inhibitor of HMG-CoA Reductase, on Serum Lipids in Healthy Volunteers
  Atherosclerosis, 1986
• CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species
  Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1986
• The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease
  JAMA, 1984
• Inhibition of Cholesterol Synthesis in vitro and in vivo by ML‐236A and ML‐236B, Competitive Inhibitors of 3‐Hydroxy‐3‐methylglutaryl‐Coenzyme A Reductase
  European Journal of Biochemistry, 1977
• THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM
  Journal of Clinical Investigation, 1955